FourThought Financial LLC Has $252,000 Stock Holdings in Sanofi (NASDAQ:SNY)

FourThought Financial LLC lowered its position in shares of Sanofi (NASDAQ:SNY – Get Rating) by 11.1% in the third quarter, Holdings Channel reports. The institutional investor owned 6,635 shares of the company’s stock after selling 826 shares during the period. FourThought Financial LLC’s holdings in Sanofi were worth $252,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of the business. MGO One Seven LLC raised its stake in Sanofi by 5.2% in the 2nd quarter. MGO One Seven LLC now owns 4,815 shares of the company’s stock worth $241,000 after purchasing an additional 239 shares in the last quarter. Captrust Financial Advisors raised its position in shares of Sanofi by 0.9% in the third quarter. Captrust Financial Advisors now owns 26,191 shares of the company’s stock valued at $996,000 after buying an additional 246 shares in the last quarter. Pinnacle Financial Partners Inc. boosted its stake in shares of Sanofi by 5.0% in the third quarter. Pinnacle Financial Partners Inc. now owns 5,527 shares of the company’s stock valued at $210,000 after buying an additional 261 shares during the period. Checchi Capital Advisers LLC grew its position in Sanofi by 1.6% during the third quarter. Checchi Capital Advisers LLC now owns 16,520 shares of the company’s stock worth $628,000 after buying an additional 261 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC increased its stake in Sanofi by 6.5% during the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 4,253 shares of the company’s stock worth $162,000 after acquiring an additional 261 shares during the period. Institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on SNY. The Goldman Sachs Group started coverage on Sanofi in a research report on Friday, December 16th. They set a “buy” rating for the company. TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, December 2nd. Finally, Morgan Stanley restated an “overweight” rating on shares of Sanofi in a research report on Tuesday, December 13th. Five research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Sanofi Price Performance

SNY stock opened at $47.74 on Friday. Sanofi has a 1 year low of $36.91 and a 1 year high of $58.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.42 and a quick ratio of 1.05. The stock has a market cap of $120.38 billion, a price-to-earnings ratio of 16.87, a P/E/G ratio of 1.47 and a beta of 0.54. The company has a 50 day simple moving average of $47.98 and a 200 day simple moving average of $44.96.

Sanofi (NASDAQ:SNY – Get Rating) last announced its quarterly earnings results on Friday, February 3rd. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Sanofi had a net margin of 15.70% and a return on equity of 28.00%. The firm had revenue of $10.95 billion during the quarter, compared to the consensus estimate of $11.51 billion. Research analysts anticipate that Sanofi will post 4.4 EPS for the current fiscal year.

Sanofi Cuts Dividend

The firm also recently announced an annual dividend, which will be paid on Friday, June 23rd. Shareholders of record on Wednesday, May 31st will be issued a dividend of $1.377 per share. This represents a yield of 2.94%. The ex-dividend date of this dividend is Tuesday, May 30th. Sanofi’s payout ratio is 44.52%.

About Sanofi

(Get Rating)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.